TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9272427

Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous HRT (25 or 50 micrograms/day of transdermal 17 beta‐estradiol plus medrogestone 5 mg/day for 12 days/month)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg/day plus 17 beta‐estradiol 25 micrograms/day plus medrogestone 5 mg/day for 12 days/month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium 500 mg/day (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose HRT (not specified)
Number of subjects: 0
Study: 30141290

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with local exercise (active acupuncture group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture (control group)
Number of subjects: 60
Study: 27513651

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 21727

Group type: EXPERIMENTAL
Intervention: Baseline low-density lipoprotein cholesterol (LDL-C)
Number of subjects: 21727

Group type: EXPERIMENTAL
Intervention: Baseline SBP and LDL-C in the diabetic subgroup
Number of subjects: 21727
Study: 25395844

Group type: EXPERIMENTAL
Intervention: BodyBalance training (2 sessions per week for 12 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal activities (control group)
Number of subjects: 28
Study: 23844570

Group type: EXPERIMENTAL
Intervention: Remote patient reporting of health status parameters and linked health behavior change feedback (n=24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard of care including diabetes education and healthcare provider counseling (n=24)
Number of subjects: 48
Study: 19524315

Group type: EXPERIMENTAL
Intervention: Systematic prophylactic gastrostomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No systematic gastrostomy
Number of subjects: 0
Study: 18543683

Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 26
Study: 15473114

Group type: EXPERIMENTAL
Intervention: Rigid foot orthoses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 11810122

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Number of subjects: 307

Group type: COMPARATOR
Intervention: Combination of normobaric plus hyperbaric oxygen therapy
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Dizziness before admission
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Headaches upon hospital admission
Number of subjects: 307
Study: 10073211

Group type: EXPERIMENTAL
Intervention: Targeted community-wide interventions to increase mammography screening rates.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control community (no intervention).
Number of subjects: 0
Study: 7979936

Group type: EXPERIMENTAL
Intervention: Wrist splinting at 20 degrees extension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wrist splinting at neutral angle
Number of subjects: 0
Study: 2498571

Group type: EXPERIMENTAL
Intervention: 2-(3-Methylcinnamylhydrazono)-Propionate (MCHP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 1207435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (7 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg)
Number of subjects: 0
Study: 30661687

Group type: EXPERIMENTAL
Intervention: 25(OH)VitD 2.000 IU/day p.o. (Suppl group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No supplementation (No-Suppl group)
Number of subjects: 50
Study: 29131090

Group type: EXPERIMENTAL
Intervention: Online self-help program (Deprexis)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Active control group (weekly online information on depression)
Number of subjects: 229
Study: 24821459

Group type: EXPERIMENTAL
Intervention: Improved fixation method using an indwelling needle and membrane cover
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional fixation method using a haemostat, elastic band and abdominal bandage
Number of subjects: 65
Study: 23965772

Group type: EXPERIMENTAL
Intervention: Recent sex with a man
Number of subjects: 2146

Group type: EXPERIMENTAL
Intervention: Reported bisexual behavior
Number of subjects: 2146

Group type: EXPERIMENTAL
Intervention: Number of study visits with recent sex with men
Number of subjects: 2146
Study: 21812890

Group type: EXPERIMENTAL
Intervention: Premeal insulin glulisine
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Postmeal insulin glulisine
Number of subjects: 322
Study: 19345987

Group type: EXPERIMENTAL
Intervention: Robotic radical hysterectomy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Laparoscopic radical hysterectomy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Radical abdominal hysterectomy
Number of subjects: 63
Study: 17468795

Group type: EXPERIMENTAL
Intervention: Traditional physiotherapy with home training
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Traditional physiotherapy without home training
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: New sling exercise therapy with home training
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: New sling exercise therapy without home training
Number of subjects: 214
Study: 15464258

Group type: EXPERIMENTAL
Intervention: Bioartificial liver (BAL)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control
Number of subjects: 171
Study: 11587278

Group type: EXPERIMENTAL
Intervention: Low‐peroxidase diet group
Number of subjects: 1203

Group type: COMPARATOR
Intervention: No diet group
Number of subjects: 1203
Study: 9439546

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 0
Study: 8178325

Group type: EXPERIMENTAL
Intervention: Algorithm (Group A)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard therapy (Group S)
Number of subjects: 66
Study: 3067735

Group type: EXPERIMENTAL
Intervention: Subunit vaccine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Whole virus vaccine
Number of subjects: 102
Study: 31744798

Group type: EXPERIMENTAL
Intervention: LOADING group (3 monthly injections followed by as needed)
Number of subjects: 82

Group type: COMPARATOR
Intervention: PRN group (treated as needed from the beginning)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: LOADING group
Number of subjects: 82

Group type: COMPARATOR
Intervention: PRN group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 31061013

Group type: EXPERIMENTAL
Intervention: KIDNEYTEXT intervention group receiving three text messages per week for 6 months providing customised dietary information and advice based on renal dietary guidelines and general healthy eating dietary guidelines.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 130
Study: 27784687

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (placebo)
Number of subjects: 10
Study: 26248150

Group type: EXPERIMENTAL
Intervention: Spiral flow-generating tube (protocol A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional connecting tube (protocol B)
Number of subjects: 100
Study: 23327349

Group type: EXPERIMENTAL
Intervention: Low plasma citrulline levels
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lowest citrulline quartile
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Citrulline levels
Number of subjects: 135
Study: 21277674

Group type: EXPERIMENTAL
Intervention: EE 20 μg/drsp 3mg in a 24/4 regimen for 7 or 13 cycles
Number of subjects: 2386
Study: 19627679

Group type: EXPERIMENTAL
Intervention: Strength training intervention for 12 weeks
Number of subjects: 3
Study: 17434511

Group type: EXPERIMENTAL
Intervention: GnRH-a (tryptorelin or leuprorelin, 3.75 mg every 28 days)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Continuous estroprogestin (ethynilestradiol, 0.03 mg plus gestoden, 0.75 mg)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Dietary therapy (vitamins, minerals salts, lactic ferments, fish oil)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Surgery plus placebo
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Postoperative medical and dietary therapy
Number of subjects: 222
Study: 15366275

Group type: EXPERIMENTAL
Intervention: Realism framework in evidence based medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence based medicine adopting realism
Number of subjects: 0
Study: 11820707

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily for 3 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 9552063

Group type: EXPERIMENTAL
Intervention: sCD30 levels measured at diagnosis and after induction polychemotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: sCD30 levels
Number of subjects: 70
Study: 8151464

Group type: EXPERIMENTAL
Intervention: Calcitriol (17.1 ± 5.9 ng/kg per day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Dihydrotachysterol (13.8 ± 3.3 micrograms/kg per day)
Number of subjects: 94
Study: 2453990

Group type: EXPERIMENTAL
Intervention: TRUE Test (TT)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Finn Chamber (FC)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: TRUE Test (TT) and Finn Chamber (FC)
Number of subjects: 292
Study: 30924372

Group type: EXPERIMENTAL
Intervention: Nonopioid medications
Number of subjects: 68

Group type: COMPARATOR
Intervention: Opioid medications
Number of subjects: 68
Study: 31543973

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 64

Group type: COMPARATOR
Intervention: Insulin detemir (IDet)
Number of subjects: 64
Study: 30184007

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (2mA for five 20-min sessions)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study: 26523398

Group type: EXPERIMENTAL
Intervention: Instructional self-statement
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Motivational auditory feedback
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vicarious experiences
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Verbal persuasion
Number of subjects: 96
Study: 25183741

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 188

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 188
Study: 22094303

Group type: EXPERIMENTAL
Intervention: Individualised patient care as an adjunct to standard care
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 127
Study: 20846586

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 945

Group type: COMPARATOR
Intervention: Imipenem/Cilastatin
Number of subjects: 945
Study: 17591563

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy (Cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy with rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dose-dense and/or dose-intense regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 0
Study: 15867495

Group type: EXPERIMENTAL
Intervention: Couple-focused adherence intervention
Number of subjects: 215

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215
Study: 11937621

Group type: EXPERIMENTAL
Intervention: Needle-exchange program (NEP); n = 296; median follow-up = 261 days
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Needle-exchange program (NEP) users; n = 65; median follow-up = 199 days
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: NEP usage predictors
Number of subjects: 600
Study: 9861598

Group type: EXPERIMENTAL
Intervention: Cycling at 80% VO2max
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cycling at 60% VO2max
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resting BE
Number of subjects: 12
Study: 7829792

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Number of subjects: 14916

Group type: COMPARATOR
Intervention: Fish oil consumption
Number of subjects: 14916
Study: 2396473

Group type: EXPERIMENTAL
Intervention: Parotin (oral adjuvant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taurine (oral adjuvant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taurine + Lithium (oral adjuvant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taurine + Parotin (oral adjuvant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taurine + Parotin + Lithium (oral adjuvant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taurine + Lithium + Parotin (oral adjuvants)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccines (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adjuvant control group
Number of subjects: 0
Study: 314716

Group type: EXPERIMENTAL
Intervention: Sufentanil (SF)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fentanyl (F)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both analgesics
Number of subjects: 54
Study: 31951627

Group type: EXPERIMENTAL
Intervention: Medium rejection
Number of subjects: 121

Group type: COMPARATOR
Intervention: Included
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Severe rejection
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High rejection sensitivity
Number of subjects: 121
Study: 31722374

Group type: EXPERIMENTAL
Intervention: Anti-hyperglycemic medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mendelian Randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical implications for patients with obesity, diabetes, and cancer
Number of subjects: 0
Study: 28846769

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 377
Study: 25676203

Group type: EXPERIMENTAL
Intervention: Thoracoscopic esophagectomy
Number of subjects: 379
Study: 23141816

Group type: EXPERIMENTAL
Intervention: Serelaxin (30 μg/kg per day)
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1161
Study: 21787070

Group type: EXPERIMENTAL
Intervention: Behavioral activation-enhanced orientation classes (n = 37)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control orientation as usual classes (n = 34)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 19217991

Group type: EXPERIMENTAL
Intervention: Fixed-dose warfarin 1 mg per day
Number of subjects: 1590

Group type: EXPERIMENTAL
Intervention: Dose-adjusted warfarin
Number of subjects: 1590

Group type: COMPARATOR
Intervention: No warfarin
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Warfarin (combined fixed-dose and dose-adjusted)
Number of subjects: 1590
Study: 17141179

Group type: EXPERIMENTAL
Intervention: Training to resolve descriptions of ambiguous events positively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Test-retest control condition
Number of subjects: 0
Study: 15219265

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg bid)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg bid)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Formoterol and Salmeterol
Number of subjects: 35
Study: 11711322

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 58

Group type: COMPARATOR
Intervention: Buffered regular human insulin
Number of subjects: 58
Study: 9385624

Group type: EXPERIMENTAL
Intervention: 75 mg of immediate-release PPA (administered orally via a gelatin capsule)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7611920

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg/day for 8 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nifedipine (40 mg/day b.i.d. for 8 weeks)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 106
Study: 3494711

Group type: EXPERIMENTAL
Intervention: Inpatient teaching programs
Number of subjects: 0
Study: 29112242

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP+)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cyclosporine and methotrexate with methylprednisolone (MP+)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cyclosporine and methotrexate without methylprednisolone (MP-)
Number of subjects: 108
Study: 28318161

Group type: EXPERIMENTAL
Intervention: Periodontal therapy and root-canal treatment (experimental group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Periodontal treatment alone (control group)
Number of subjects: 180
Study: 24005884

Group type: COMPARATOR
Intervention: Port devices
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PICC lines
Number of subjects: 70
Study: 22381566

Group type: EXPERIMENTAL
Intervention: 3D computerised planning
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2D templating
Number of subjects: 60
Study: 16450574

Group type: EXPERIMENTAL
Intervention: Desloratadine/pseudoephedrine, 2.5/120 mg b.i.d.
Number of subjects: 650

Group type: COMPARATOR
Intervention: Desloratadine, 5 mg once per day
Number of subjects: 650

Group type: COMPARATOR
Intervention: Pseudoephedrine, 120 mg b.i.d.
Number of subjects: 650
Study: 12378662

Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg ml‐1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg ml‐1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg ml‐1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg ml‐1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1.0% Ropivacaine
Number of subjects: 64
Study: 9924905

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 1 g/day
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 3 g/day
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 6 g/day
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 8849986

Group type: EXPERIMENTAL
Intervention: Isoflurane 2% administered before sternotomy for ten minutes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane 2% administered after sternotomy for ten minutes
Number of subjects: 30
Study: 2153777

Group type: EXPERIMENTAL
Intervention: Programmed Unit of Instruction (PUI) for infection control
Number of subjects: 108

Group type: COMPARATOR
Intervention: Lecture format for infection control (Control)
Number of subjects: 108
Study: 7367947

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 1

Group type: COMPARATOR
Intervention: Sham dialysis
Number of subjects: 1
Study: 29554379

Group type: EXPERIMENTAL
Intervention: Virtual Surgical Training System (VSTS) - Simulation Training (ST) group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Introductory teaching session - Control group
Number of subjects: 10
Study: 28608719

Group type: EXPERIMENTAL
Intervention: Home monitoring intervention with spirometry and symptom monitoring twice per week.
Number of subjects: 267

Group type: COMPARATOR
Intervention: Usual care arm (seen every 3 months, contact if worsening symptoms).
Number of subjects: 267
Study: 24973731

Group type: EXPERIMENTAL
Intervention: Functionally orientated treatment (SDA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Removable partial dentures (RPD)
Number of subjects: 89
Study: 23827658

Group type: EXPERIMENTAL
Intervention: Training, support, and activity therapy intervention
Number of subjects: 304

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 304
Study: 21192270

Group type: EXPERIMENTAL
Intervention: CobraPLUS
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cookgas air-Q
Number of subjects: 180

Group type: COMPARATOR
Intervention: Fastrach ILMA
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: CobraPLUS, Cookgas air-Q, Fastrach ILMA
Number of subjects: 180
Study: 18490886

Group type: EXPERIMENTAL
Intervention: Foot reflexotherapy (20 minutes during postoperative days 2, 3, and 4)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual pain management
Number of subjects: 61
Study: 17062449

Group type: EXPERIMENTAL
Intervention: Long-term multi-session intervention
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Short-term single session intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 54
Study: 12921496

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate 50 mg intravenous piggyback (IVPB) prior to infusion and repeated 1 hour into the infusion
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard regimen of acetaminophen 650 mg orally with diphenhydramine 50 mg intravenously
Number of subjects: 143
Study: 10872150

Group type: EXPERIMENTAL
Intervention: MR angiography (MRA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined readings of MRA and DSA
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intermethod agreement
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MRA and DSA
Number of subjects: 34
Study: 9477787

Group type: EXPERIMENTAL
Intervention: Autogeneic, allogeneic, and alloplastic sinus grafts (individually or mixed)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Root form implants placed in augmented sinuses
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mean Periotest value at uncovering
Number of subjects: 27
Study: 1587197

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3544625

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (KABI 2165) 5,000 U once daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional heparin 5,000 IU twice daily
Number of subjects: 52
Study: 30961460

Group type: EXPERIMENTAL
Intervention: Omega-3 (2 g) plus Vitamin E (400 IU)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62